Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $27

Raymond James analyst Steven Seedhouse maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $28 to $27.
byBenzinga Newsdesk
November 2, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Raymond James analyst Steven Seedhouse maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $28 to $27.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Ark Invest, Cathie Wood Raise $16 Million For New Crypto Funds: Why Most Investors Will Be Unable To Participate

By Chris Katje
March 17, 2:49 PM
Over the years, Ark Invest CEO Cathie Wood has been a vocal supporter of the cryptocurrency sector. Ark Invest has included several crypto-friendly companies among big ETF holdings. The company is rolling out new crypto investment funds, but they might not be readily available to everyone.

ARKF